Valeant Pharmaceuticals was created in 1960.
Librax is manufactured by Valeant Pharmaceuticals International
ICN Pharmaceuticals and Valeant Pharmaceuticals have a historical connection through a series of corporate transactions. ICN Pharmaceuticals, originally founded in 1959 by Milan Panić, was a multinational pharmaceutical company based in California, USA. It was involved in the development, manufacturing, and marketing of a range of pharmaceutical products. Valeant Pharmaceuticals, formerly known as ICN Pharmaceuticals, changed its name in 2003. The rebranding was part of a strategic decision to distance itself from past legal and financial issues and to focus on a new direction for the company. The name change from ICN Pharmaceuticals to Valeant Pharmaceuticals marked a significant transformation in the company's identity and strategic direction. Valeant pursued an aggressive acquisition strategy, acquiring numerous pharmaceutical companies and building a diverse portfolio of products across various therapeutic areas. However, it's important to note that while Valeant Pharmaceuticals evolved from ICN Pharmaceuticals, they are distinct entities with separate corporate structures, leadership, and operations. The connection between the two companies lies in their corporate history and the transformation that took place when ICN Pharmaceuticals rebranded as Valeant Pharmaceuticals.
Glenmark Pharmaceuticals was created in 1977.
Endo Pharmaceuticals was created in 1997.
BioCryst Pharmaceuticals was created in 1986.
OSI Pharmaceuticals was created in 1983.
Anthera Pharmaceuticals was created in 2004.
Emcure Pharmaceuticals was created in 1983.
Watson Pharmaceuticals was created in 1984.
ISTA Pharmaceuticals was created in 1992.
Torrent Pharmaceuticals was created in 1959.
Lexicon Pharmaceuticals was created in 1995.